GENESIS (NCT 03246529) is a 2-part, Phase-3, randomized, double-blind, placebo-controlled, multicenter study evaluating the safety and efficacy of APHEXDA (motixafortide) plus filgrastim (G-CSF), ...

-- Poster presentation of MGTA-145 investigator-initiated Phase 2 clinical trial data confirmed previously reported positive topline clinical data for stem cell mobilization and transplant in multiple ...

Individuals will be notified before the event if their poster has been accepted for presentation. NOTE: If your abstract is accepted, you will be asked to be available at your poster during half of ...

BASEL, Switzerland & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cimeio Therapeutics, a biotechnology company that is the leader of the field of epitope editing, today announced the acceptance of two abstracts ...

Stem cell scientists earn recognition for their research at ISSCR's International Symposium this month in Athens, Greece. Pictured left to right: Alice Rossi, PhD, Angeliki Spathopoulou, PhD, and ...